BioSpace News Archive

Loxo Oncology completed the rolling submission of its New Drug Application (INDA) to the U.S. FDA for larotrectinib for adult and pediatric metastatic solid tumors with an NTRK gene fusion. What has caught many investors, analysts and industry observers off-guard is the way the company has downplayed the drug’s potential sales.

Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.

TFF Pharmaceuticals closed on a Series A financing worth $14 million. The funds will be used to advance the company’s pipeline of dry powder drugs for pulmonary diseases and other conditions.

Amgen gets to breathe a small, but temporary sigh of relief as a court case determining whether or not Novartis subsidiary Sandoz can launch its biosimilar challenge to blockbuster rheumatoid arthritis drug Enbrel has been delayed.

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) launched an educational suite dubbed the “Parkinson’s Clinical Trial Companion.”

Dermavant Sciences, a company founded by biotech guru Vivek Ramaswamy, tapped former GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer.

Pfizer Inc. may have a new potential buyer for its consumer health business unit. Mega-consumer goods company Procter & Gamble is reportedly interested in acquiring the business.

More than a dozen advertisers, including Johnson & Johnson and Bayer, have boycotted the Fox News show, “The Ingraham Angle,” after its host, Laura Ingraham, 54, bullied high school student David Hogg.

Rigel Pharmaceuticals reported a developmental setback for Tavalisse in a mid-stage kidney disease trial. Investors began dumping shares and the stock was down nearly 10 percent.

Pfizer, based in New York City, and Allogene Therapeutics, based in South San Francisco, entered into an asset contribution deal, as well as a $300 million Series A round.